Vapotherm announces proposed public offering of common stock

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 465,750 shares of its common stock at the public offering price less underwriting discounts and

2 Aug 2019 Vapotherm said the underwriters have 30 days to buy up to an additional 465,750 shares of its common stock at the public offering price. Exeter  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock. Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 465,750 shares of its common stock at the public offering price less underwriting discounts and Vapotherm Announces Proposed Public Offering of Common Stock Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share.

VAPO Vapotherm, Inc. daily Stock Chart Jul-30-19 04:11PM, Vapotherm Announces Proposed Public Offering of Common Stock Business Wire -5.47%.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share. Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock. Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to

13 Nov 2018 In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock, at the 

13 Nov 2018 In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock, at the  20 Feb 2020 Westport, CT, Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ( Nasdaq: BSGM) (“BioSig” or the “Company”), a medical  This is an initial public offering of common stock of Vapotherm, Inc. We are selling used in our Precision Flow systems, we may be required to raise our prices,  VAPO Vapotherm, Inc. daily Stock Chart Jul-30-19 04:11PM, Vapotherm Announces Proposed Public Offering of Common Stock Business Wire -5.47%. View breaking news headlines for VAPO stock from trusted media outlets at MarketBeat. Vapotherm Announces Proposed Public Offering of Common Stock Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also  2 Aug 2019 Exeter, N.H.-based VapoTherm said it plans to float 3.1 million shares at $14.50 apiece for gross proceeds of $45.0 million. The offering also 

All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock.

In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 465,750 shares of its common stock at the public offering price less underwriting discounts and Vapotherm Announces Proposed Public Offering of Common Stock Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share. Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock. Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to

All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock.